By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: Phase III Data Published In The Lancet Oncology Shows A Significant Overall Survival Benefit Of Giotrif (Afatinib) Compared To Tarceva(Erlotinib) 7/6/2015 11:14:22 AM
Boehringer Ingelheim Release: New Advance In COPD Maintenance Treatment, Spiolto Respimat, Approved In First European Countries 7/2/2015 9:42:04 AM
Hikma (HIK.L) Rumored to Be Bidding $2.2B for Boehringer Ingelheim's Roxane Laboratories, As Mallinckrodt (MNK), Perrigo (PRGO) Circle 6/30/2015 6:06:29 AM
Boehringer Ingelheim Phase III Pradax Anticoagulant Antidote Study Meets Primary Endpoints 6/22/2015 6:41:54 AM
FORMA Therapeutics, Inc. Announces Achievement Of Multiple Collaboration Milestones With Boehringer Ingelheim For Modulating Protein-Protein Interactions 6/17/2015 10:15:40 AM
Boehringer Ingelheim Release: New Publication In The Lancet Describes Effective Reversal Of Pradaxa In Healthy Volunteers 6/16/2015 11:43:20 AM
Phase I Data Published in The Lancet Show Boehringer Ingelheim's Idarucizumab Reverses Anticoagulant Effects of Dabigatran 6/16/2015 8:02:06 AM
Boehringer Ingelheim Release: National Institute for Clinical Excellence (NICE) Recommends VARGATEF (Nintedanib*) In Combination With Docetaxel As An Option For Patients With Non-Small Cell Lung Cancer Of Adenocarcinoma Histology Within Its Licensed Indication 6/3/2015 11:09:26 AM
Boehringer Ingelheim Statement On Proposed CT Tax Increases 6/3/2015 10:27:22 AM
Boehringer Ingelheim’s Vargatef (Nintedanib) In Combination With Docetaxel Is Recommended As A Treatment Option Within Its Marketing Authorisation For Patents With A Common Type Of Lung Cancer 6/2/2015 11:17:28 AM